National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.
[OBJECTIVES] To develop Colombian, evidence-informed consensus recommendations for perioperative systemic therapy and unresectable stage III non-small cell lung cancer (NSCLC), considering local testi
APA
Bruges Maya R, Lombana M, et al. (2026). National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.. Expert review of anticancer therapy, 1-9. https://doi.org/10.1080/14737140.2026.2653635
MLA
Bruges Maya R, et al.. "National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.." Expert review of anticancer therapy, 2026, pp. 1-9.
PMID
41921504
Abstract
[OBJECTIVES] To develop Colombian, evidence-informed consensus recommendations for perioperative systemic therapy and unresectable stage III non-small cell lung cancer (NSCLC), considering local testing and access constraints.
[METHODS] Three Colombian professional societies conducted a modified Delphi process. A multidisciplinary panel completed two anonymous rating rounds in September 2024 and a structured debate. A systematic literature search (2010-2024) informed 34 draft statements spanning diagnostic workup, neoadjuvant and adjuvant therapy, and unresectable stage III management.
[RESULTS] Consensus was reached for 33/34 statements (97.1%). The panel endorsed multidisciplinary tumor board review and pretreatment molecular profiling. For resectable stage II-III disease without sensitizing EGFR/ALK alterations, neoadjuvant chemo-immunotherapy was preferred. For unresectable stage III, chemoradiotherapy followed by durvalumab consolidation was endorsed for PD-L1-positive tumors; use in PD-L1 tumor proportion score < 1% should be individualized. In EGFR-mutated unresectable stage III disease, durvalumab was not endorsed; osimertinib consolidation was favored. The only non-consensus item was adjuvant atezolizumab for PD-L1 ≥1% after platinum chemotherapy in EGFR/ALK-negative stage II-IIIA disease (AJCC 7th), lacking INVIMA approval at the time.
[CONCLUSION] This Delphi consensus provides a practical national framework for perioperative and unresectable stage III NSCLC management in Colombia.
[METHODS] Three Colombian professional societies conducted a modified Delphi process. A multidisciplinary panel completed two anonymous rating rounds in September 2024 and a structured debate. A systematic literature search (2010-2024) informed 34 draft statements spanning diagnostic workup, neoadjuvant and adjuvant therapy, and unresectable stage III management.
[RESULTS] Consensus was reached for 33/34 statements (97.1%). The panel endorsed multidisciplinary tumor board review and pretreatment molecular profiling. For resectable stage II-III disease without sensitizing EGFR/ALK alterations, neoadjuvant chemo-immunotherapy was preferred. For unresectable stage III, chemoradiotherapy followed by durvalumab consolidation was endorsed for PD-L1-positive tumors; use in PD-L1 tumor proportion score < 1% should be individualized. In EGFR-mutated unresectable stage III disease, durvalumab was not endorsed; osimertinib consolidation was favored. The only non-consensus item was adjuvant atezolizumab for PD-L1 ≥1% after platinum chemotherapy in EGFR/ALK-negative stage II-IIIA disease (AJCC 7th), lacking INVIMA approval at the time.
[CONCLUSION] This Delphi consensus provides a practical national framework for perioperative and unresectable stage III NSCLC management in Colombia.